Smart Money Buying the Price Weakness of Eli Lilly and Company (LLY)
- Author: Joanne Flowers Mar 17, 2017,
Mar 17, 2017, 18:09
Guggenheim Capital LLC's holdings in Eli Lilly and were worth $45,302,000 as of its most recent SEC filing. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Bank of New York Mellon Corp boosted its stake in shares of Eli Lilly and by 6.9% in the third quarter. Franklin Resources Inc. increased its position in Eli Lilly and by 13.4% in the fourth quarter. Tarbox Group Inc. now owns 1,539 shares of the company's stock worth $124,000 after buying an additional 11 shares in the last quarter.
Pharma major Eli Lilly and Company on Thursday announced launch Humalog 200U/mL KwikPen - used in the treatment of diabetes - in the Indian market. Integrated Wealth Management now owns 1,389 shares of the company's stock worth $112,000 after buying an additional 50 shares during the last quarter.
Eli Lilly and Company (NYSE:LLY) went up 1.68% during trading on the U.S. exchange when it had traded 4.88M shares. Eli Lilly and Co has a 12 month low of $64.18 and a 12 month high of $84.77. The firm has a market capitalization of $88.42 billion, a price-to-earnings ratio of 32.61 and a beta of 0.30.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, January 31st. When we look at the Volatility of the company, Week Volatility is at 1.31% whereas Month Volatility is at 1.46%. Eli Lilly and had a return on equity of 24.74% and a net margin of 12.90%. The company had revenue of $5.76 billion for the quarter, compared to analyst estimates of $5.54 billion. The share price has declined -0.74% from its top level in 52 weeks and dropped 15.17% this year.
On October 25, 2016, it reported earnings at $0.88 a share compared with the consensus estimate of $0.96 per share (negative surprise of -8.33%). For the next 5 years, Eli Lilly and Company is expecting Growth of 12.31% per annum, whereas in the past 5 years the growth was -1.25% per annum. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States & global copyright and trademark law. Equities analysts anticipate that Eli Lilly and Co will post $4.10 earnings per share for the current year.
Several other research firms have also recently issued reports on LLY. 20 Analysts reported that the Price Target for Eli Lilly and Company might touch $103 high while the Average Price Target and Low price Target is $86.55 and $70 respectively. Zacks Investment Research cut Eli Lilly and from a "buy" rating to a "hold" rating in a report on Wednesday, February 15th. Eli Lilly and presently has a consensus rating of "Buy" and a consensus price target of $86.42. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Research Analysts at Zacks has the stock a rating of 3, which implies that the firms recommendation is Neutral on the company. The average revenue estimate for the year ending December 2017 is $22.14B by 17 analysts.
For the current week, the company shares have a recommendation consensus of Buy. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director R David Hoover bought 500 shares of the stock in a transaction on Friday, December 16th. The most recent short interest data show 1.1% of the company's stock are short sold. The number of shares now owned by investors are 1.11 bln. The disclosure for this sale can be found here. Bank of New York Mellon Corp now owns 15,164,215 shares of the company's stock worth $1,217,080,000 after buying an additional 984,404 shares during the last quarter.